AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30706508 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) 500 mg
Number of subjects: 16
Study 30706508 — intervention group
Group type: COMPARATOR
Intervention: NIC gum 2 mg
Number of subjects: 16
Study 27889366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 162
Study 27889366 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 162
Study 26356396 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine aescinat
Number of subjects: 40
Study 26356396 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 23256139 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-fortified milk (250 mL daily providing 196 retinol equivalents/d) for 3 months
Number of subjects: 27
Study 21277984 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 62
Study 21277984 — intervention group
Group type: COMPARATOR
Intervention: NaCl (0.9%)
Number of subjects: 62
Study 21277984 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-mediated suggestion
Number of subjects: 62
Study 19343439 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI group (BMI >= 25 kg/m²)
Number of subjects: 1485
Study 19343439 — intervention group
Group type: COMPARATOR
Intervention: Low BMI group (BMI < 25 kg/m²)
Number of subjects: 1485
Study 17409404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 17409404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (high expression of cancer testis antigen and proliferation‐associated genes)
Number of subjects: 0
Study 15567009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 135
Study 15567009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 11515891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring of infection control practices (149 practices) in the operating room and intensive care unit
Number of subjects: 106
Study 9576071 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion CEA
Number of subjects: 1353
Study 9576071 — intervention group
Group type: COMPARATOR
Intervention: Standard CEA
Number of subjects: 1353
Study 7936830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent Escherichia coli isolates from NEC cases
Number of subjects: 17
Study 7936830 — intervention group
Group type: COMPARATOR
Intervention: Adherent Escherichia coli isolates from control infants
Number of subjects: 17
Study 7936830 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with Gram-positive isolates from control children
Number of subjects: 17
Study 7936830 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection with Gram-positive isolates from NEC cases
Number of subjects: 17
Study 3340287 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 24
Study 3340287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29759104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with mainly SFA (40 E%)
Number of subjects: 27
Study 29759104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with mainly PUFA (40 E%)
Number of subjects: 27
Study 28132005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy shock wave therapy plus eccentric exercises
Number of subjects: 93
Study 28132005 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment plus eccentric exercises
Number of subjects: 93
Study 26573453 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 41
Study 26573453 — intervention group
Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 41
Study 23946609 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection
Number of subjects: 192
Study 23946609 — intervention group
Group type: COMPARATOR
Intervention: Traditional external dissection and internal ligation
Number of subjects: 192
Study 21167351 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1540
Study 21167351 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1540
Study 19342358 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in HIV/AIDS preventive education (IG2)
Number of subjects: 339
Study 19342358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses alone (IG1)
Number of subjects: 339
Study 19342358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 339
Study 16686958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Cisplatin, 5-Fluorouracil and Interferon alpha with external beam radiation
Number of subjects: 1
Study 14967870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/moderate protein diet (HFMP; 61% fat)
Number of subjects: 20
Study 14967870 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; 25% fat)
Number of subjects: 20
Study 10928433 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine alone
Number of subjects: 30
Study 10928433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine plus fentanyl 1 microg kg(‐1)
Number of subjects: 30
Study 8657239 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot assay for KSHV antigens
Number of subjects: 40
Study 8657239 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot assay over a period of 13 to 103 months
Number of subjects: 40
Study 1423954 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion with 200-300-J shocks
Number of subjects: 112
Study 1423954 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion with 300-360-J shocks
Number of subjects: 112
Study 1423954 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion
Number of subjects: 112
Study 1423954 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion
Number of subjects: 112
Study 1423954 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 112
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus of 10.0‐50.0 U/h according to glycosuria (Group A)
Number of subjects: 24
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 2.5 U/h (Group B)
Number of subjects: 24
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 5.0 U/h (Group C)
Number of subjects: 24
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 7.5 U/h (Group D)
Number of subjects: 24
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 10.0 U/h (Group E)
Number of subjects: 24
Study 2935094 — intervention group
Group type: COMPARATOR
Intervention: No insulin given (Non-diabetic patients - NDP)
Number of subjects: 24
Study 2935094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 2.5 U/h in a patient with advanced chronic renal failure (CRF)
Number of subjects: 24
Study 31479947 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment
Number of subjects: 908
Study 30315600 — intervention group
Group type: EXPERIMENTAL
Intervention: Baitfish purchased from retail dealers
Number of subjects: 5400
Study 27029654 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSealTM laryngeal mask airway (PLMA)
Number of subjects: 44
Study 27029654 — intervention group
Group type: COMPARATOR
Intervention: ClassicTM laryngeal mask airway (CLMA)
Number of subjects: 44
Study 24852204 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-P (mini-laparoscopic-assisted LESS pyeloplasty)
Number of subjects: 30
Study 24852204 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-PN (mini-laparoscopic-assisted LESS partial nephrectomy)
Number of subjects: 30
Study 24852204 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-RP (mini-laparoscopic-assisted LESS radical prostatectomy)
Number of subjects: 30
Study 22510472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education at their homes (House Calls)
Number of subjects: 180
Study 22510472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-Based education in the transplant center
Number of subjects: 180
Study 22510472 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Counseling in the transplant center
Number of subjects: 180
Study 19176186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid ankle-foot orthosis (R-AFO)
Number of subjects: 11
Study 19176186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthosis (D-AFO)
Number of subjects: 11
Study 19176186 — intervention group
Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 11
Study 17224716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 58
Study 17224716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 16084762 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 73
Study 16084762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 73
Study 12780979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 &micro;g/kg)
Number of subjects: 84
Study 12780979 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 84
Study 10734512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfloxacin 400 mg bd twice a day for five days
Number of subjects: 60
Study 10734512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg bd twice a day for five days
Number of subjects: 60
Study 7859136 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 0
Study 7859136 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 0
Study 7859136 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 0
Study 1954153 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene at 150 ppm
Number of subjects: 42
Study 1954153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.66 g EtOH/kg body weight
Number of subjects: 42
Study 1954153 — intervention group
Group type: COMPARATOR
Intervention: Toluene at 150 ppm (EtOH equivalents)
Number of subjects: 42
Study 6941640 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐beta‐blocker (labetalol 300 mg b.d.)
Number of subjects: 10
Study 6941640 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐beta‐blocker (propranolol 80 mg b.d.)
Number of subjects: 10
Study 6941640 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31318721 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted postgraduate education on optic disc assessment
Number of subjects: 46
Study 31318721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 28465550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 79
Study 28465550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 25715366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 357
Study 25715366 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (Control)
Number of subjects: 357
Study 25173535 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (SES)
Number of subjects: 2119
Study 25173535 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (EES)
Number of subjects: 2119
Study 23079671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad‐ECRG2 (adenoviral vector)
Number of subjects: 0
Study 19583069 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed arterial blood gas sampling and pediatric vials for phlebotomy (Group A)
Number of subjects: 39
Study 19583069 — intervention group
Group type: COMPARATOR
Intervention: Standard technique of arterial line sampling and adult vial phlebotomy (Group B)
Number of subjects: 39
Study 17631737 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy and stretching exercises (LSG, n=10)
Number of subjects: 20
Study 17631737 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises only (SG, n=10)
Number of subjects: 20
Study 15801574 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent vouchers for biochemically verified smoking abstinence
Number of subjects: 58
Study 15801574 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent vouchers earned independent of smoking status
Number of subjects: 58
Study 12413614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic transdermal 17‐beta estradiol (0.10 mg/day, Climara)
Number of subjects: 132
Study 12413614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 9636847 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 9636847 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 8593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg once daily for 10 days
Number of subjects: 18
Study 8593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily for 10 days
Number of subjects: 18
Study 8593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily for 10 days
Number of subjects: 18
Study 2649123 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural 0.5% bupivacaine with additional morphine (bolus 4 mg plus 0.5 mg h‐1)
Number of subjects: 22
Study 2649123 — intervention group
Group type: COMPARATOR
Intervention: Extradural 0.5% bupivacaine without morphine
Number of subjects: 22
Study 367851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg body weight on 2 consecutive days/week for 3 months)
Number of subjects: 21
Study 367851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29052236 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICD programming (Arm A)
Number of subjects: 1500
Study 29052236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate cut-off ICD programming (Arm B)
Number of subjects: 1500
Study 29052236 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed therapy ICD programming (Arm C)
Number of subjects: 1500
Study 26458923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program (aerobic and resistance exercises) in addition to usual care (including chemotherapy at the investigator's choice)
Number of subjects: 200
Study 26458923 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including chemotherapy at the investigator's choice)
Number of subjects: 200
Study 26458923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program
Number of subjects: 200
Study 22985217 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 312
Study 22985217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 312
Study 21288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 53
Study 21288144 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 53
Study 21288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Alprazolam and Captopril)
Number of subjects: 53
Study 19219907 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed compound for the treatment of osteoarthritis and rheumatoid arthritis
Number of subjects: 0
Study 19219907 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18551937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type‐A (BTX‐A)
Number of subjects: 27
Study 18551937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15588742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate infusion
Number of subjects: 6213
Study 15588742 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6213
Study 15588742 — intervention group
Group type: EXPERIMENTAL
Intervention: Region 2 patients (Bulgaria, Georgia, and Russia)
Number of subjects: 6213
Study 15588742 — intervention group
Group type: EXPERIMENTAL
Intervention: Region 1 patients (United States and Canada)
Number of subjects: 6213
Study 15588742 — intervention group
Group type: EXPERIMENTAL
Intervention: Region 3 patients (Austria, Belgium, Chile, Hungary, Israel, the Netherlands, New Zealand, and Venezuela)
Number of subjects: 6213
Study 11165203 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of the C allele of the AT(1) gene in hypertensive subjects with hypercholesterolemia
Number of subjects: 131
Study 11165203 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with hypercholesterolemia
Number of subjects: 131
Study 11165203 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive subjects
Number of subjects: 131
Study 9018020 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine (25-50 mg/day)
Number of subjects: 126
Study 9018020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 8361865 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 5
Study 8361865 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO)
Number of subjects: 5
Study 3007605 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100 mg orally)
Number of subjects: 6
Study 3007605 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (10 mg orally)
Number of subjects: 6
Study 30545333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of the mother including psychotherapy and pharmacotherapy (Step 1 treatment group)
Number of subjects: 143
Study 30545333 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling only for mother (Step 1 control group)
Number of subjects: 143
Study 30545333 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child training (PCT) (Step 2 for both TG and CG)
Number of subjects: 143
Study 27515756 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Stories intervention
Number of subjects: 50
Study 27515756 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50
Study 23920353 — intervention group
Group type: EXPERIMENTAL
Intervention: Online behavioural weight management (OBWM) intervention
Number of subjects: 572
Study 23920353 — intervention group
Group type: COMPARATOR
Intervention: Online basic lifestyle information (OBLI) intervention
Number of subjects: 572
Study 23920353 — intervention group
Group type: EXPERIMENTAL
Intervention: OBLI+BEV (fortified diet cola beverage)
Number of subjects: 572
Study 23920353 — intervention group
Group type: EXPERIMENTAL
Intervention: OBWM+BEV (fortified diet cola beverage)
Number of subjects: 572
Study 23920353 — intervention group
Group type: EXPERIMENTAL
Intervention: OBWM condition
Number of subjects: 572
Study 22174429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 72
Study 22174429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 72
Study 22174429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20868962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg neostigmine
Number of subjects: 60
Study 20868962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg neostigmine
Number of subjects: 60
Study 20868962 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous recovery)
Number of subjects: 60
Study 18037627 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (6 mg/day)
Number of subjects: 121
Study 18037627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 12061620 — intervention group
Group type: EXPERIMENTAL
Intervention: Children instructed to keep play activities secret
Number of subjects: 48
Study 12061620 — intervention group
Group type: COMPARATOR
Intervention: Children not instructed to keep play activities secret
Number of subjects: 48
Study 12061620 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly suggestive interview questions
Number of subjects: 48
Study 12061620 — intervention group
Group type: EXPERIMENTAL
Intervention: Less suggestive interview questions
Number of subjects: 48
Study 10530104 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% carbamide peroxide (DW)
Number of subjects: 30
Study 10530104 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing 3% hydrogen peroxide (HP)
Number of subjects: 30
Study 8091384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 516
Study 8091384 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Dimer
Number of subjects: 516
Study 8091384 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-Antithrombin complexes
Number of subjects: 516
Study 2577377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg daily escalating to 40 mg daily)
Number of subjects: 40
Study 2577377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2577377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 40
Study 1103017 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐Adenosylmethionine (25 mg i.m. three times daily)
Number of subjects: 31
Study 1103017 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (25 mg i.m. three times daily)
Number of subjects: 31
Study 28296725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 535
Study 28296725 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 535
Study 25244562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 60-min prevention lesson focusing on preventable risk factors for headache and providing instructions on stress management and neck and shoulder muscle relaxation exercises.
Number of subjects: 900
Study 25244562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 900